Andrew Kageleiry

595 total citations
23 papers, 374 citations indexed

About

Andrew Kageleiry is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Economics and Econometrics. According to data from OpenAlex, Andrew Kageleiry has authored 23 papers receiving a total of 374 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 4 papers in Economics and Econometrics. Recurrent topics in Andrew Kageleiry's work include Advanced Breast Cancer Therapies (8 papers), Cancer Treatment and Pharmacology (6 papers) and Lung Cancer Treatments and Mutations (5 papers). Andrew Kageleiry is often cited by papers focused on Advanced Breast Cancer Therapies (8 papers), Cancer Treatment and Pharmacology (6 papers) and Lung Cancer Treatments and Mutations (5 papers). Andrew Kageleiry collaborates with scholars based in United States, Canada and Switzerland. Andrew Kageleiry's co-authors include James Signorovitch, Alexa B. Kimball, Min Yang, M Sundaram, Martin M. Okun, Gregor B. E. Jemec, Parvez Mulani, Y. Gu, Elyse Swallow and Nathan Tefft and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Andrew Kageleiry

22 papers receiving 366 citations

Peers

Countries citing papers authored by Andrew Kageleiry

Since Specialization

Citations

This map shows the geographic impact of Andrew Kageleiry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Kageleiry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Kageleiry more than expected).

Fields of papers citing papers by Andrew Kageleiry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Kageleiry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Kageleiry. The network helps show where Andrew Kageleiry may publish in the future.

Co-authorship network of co-authors of Andrew Kageleiry

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Kageleiry. A scholar is included among the top collaborators of Andrew Kageleiry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Kageleiry. Andrew Kageleiry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical Outcomes Associated with Switching or Discontinuation from Anti-TNF Inhibitors for Nonmedical Reasons 2017 ·Clinical Therapeutics ·Douglas C. Wolf, Martha Skup, Hongbo Yang, (unknown), Andrew Kageleiry, Jingdong Chao, Manish Mittal, Mark Lebwohl	24
2	Public health impact of Rotarix vaccination among commercially insured children in the United States 2017 ·Vaccine ·Girishanthy Krishnarajah, Andrew Kageleiry, Caroline Korves, Patrick Lefèbvre, Mei Sheng Duh	2
3	Characteristics and outcomes of ALK+ non‐small cell lung cancer patients in Korea 2017 ·Asia-Pacific Journal of Clinical Oncology ·Sung Hee Lim, (unknown), Jong Seok Lee, (unknown), Yu Jung Kim, Se Hyun Kim, Jie Zhang, (unknown), Elyse Swallow, Andrew Kageleiry, (unknown), (unknown), Karen Stein, (unknown), Keunchil Park	6
4	Out‐of‐pocket medical costs and third‐party healthcare costs for children with Down syndrome 2016 ·American Journal of Medical Genetics Part A ·Andrew Kageleiry, (unknown), Mei Sheng Duh, Patrick Lefèbvre, John Campbell, Brian G. Skotko	22
5	Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2− metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis 2016 ·Journal of Medical Economics ·Nanxin Li, Yanni Hao, (unknown), (unknown), (unknown), Andrew Kageleiry, Eric Q. Wu, Annie Guérin	4
6	Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2− Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy 2016 ·Advances in Therapy ·Yanni Hao, Nanxin Li, (unknown), (unknown), (unknown), Andrew Kageleiry, Eric Q. Wu, Annie Guérin	9
7	Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy 2016 ·Value in Health ·Yanni Hao, (unknown), (unknown), (unknown), (unknown), Andrew Kageleiry	1
8	Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans with Schizophrenia 2016 ·The Journal of Clinical Psychiatry ·Yinong Young‐Xu, Mei Sheng Duh, Erik Muser, Maral DerSarkissian, Elizabeth Faust, Andrew Kageleiry, Rachel H. Bhak, Dong‐Jing Fu, Patrick Lefèbvre, Brian Shiner	22
9	Income Growth Trajectory For Parents Of Children With Down Syndrome In The United States 2016 ·Value in Health ·(unknown), Andrew Kageleiry, (unknown), Patrick Lefèbvre, (unknown), Maral DerSarkissian, (unknown), Brian G. Skotko	0
10	Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study 2016 ·Lung Cancer ·J. Cadranel, Keunchil Park, Óscar Arrieta, Miklos Pless, (unknown), (unknown), Medha Sasané, (unknown), Elyse Swallow, (unknown), Andrew Kageleiry, Karen Stein, (unknown), Jie Zhang	18
11	Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study 2016 ·Expert Opinion on Pharmacotherapy ·Annie Guérin, Yanni Hao, Derek Tang, (unknown), (unknown), Andrew Kageleiry, (unknown), Nanxin Li, Eric Q. Wu	3
12	Abstract P4-13-14: Time on treatment of everolimus, fulvestrant, and capecitabine for the treatment of HR+/HER2- metastatic breast cancer: A retrospective claims study in the US 2016 ·Cancer Research ·(unknown), Yanni Hao, Andrew Kageleiry, (unknown), (unknown), (unknown), A. Guérin	1
13	Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US 2015 ·Current Medical Research and Opinion ·Nanxin Li, Yanni Hao, Andrew Kageleiry, (unknown), (unknown), (unknown), Eric Q. Wu, Annie Guérin	8
14	ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer 2015 ·Cancer Epidemiology ·Annie Guérin, Medha Sasané, Jie Zhang, Alexander R. Macalalad, (unknown), (unknown), Andrew Kageleiry, Kenneth W. Culver, Eric Q. Wu, Heather A. Wakelee	13
15	Real-World Patient Characteristics, Treatment Patterns, and Survival among Locally-Advanced/Metastatic Alk+ Non-Small Cell Lung Cancer Patients in Latin America 2015 ·Value in Health ·Óscar Arrieta, (unknown), Gonzalo Recondo, Diego Kaen, (unknown), (unknown), Elyse Swallow, (unknown), (unknown), (unknown), Andrew Kageleiry, Karen Stein, (unknown), Claudio Martín	1
16	The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation 2015 ·Blood ·Franck E. Nicolini, Grzegorz Basak, Dong‐Wook Kim, Eduardo Olavarría, Javier Pinilla‐Ibarz, Jane F. Apperley, Timothy P. Hughes, Dietger Niederwieser, Michael J. Mauro, Charles Chuah, Andreas Hochhaus, Giovanni Martinelli, Maral DerSarkissian, Andrew Kageleiry, Mo Yang, Hui Huang, Lisa J. McGarry, Hagop M. Kantarjian, Jörge E. Cortes	6
17	The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas 2015 ·Current Medical Research and Opinion ·Alexander R. Macalalad, Megan McAuliffe, Hongbo Yang, Andrew Kageleiry, Yichen Zhong, Eric Q. Wu, Oluwatoyin Shonukan, Vijayveer Bonthapally	5
18	FRI0123 Clinical Outcomes Associated with Switching or Discontinuation of Anti-TNF Inhibitors for Non-Medical Reasons 2015 ·Annals of the Rheumatic Diseases ·Mark Lebwohl, Martha Skup, Hongbo Yang, Elizabeth Faust, Andrew Kageleiry, J. Chao, Douglas C. Wolf	2
19	Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2−) breast cancer patients in the United States: 2002–2012 2014 ·Current Medical Research and Opinion ·Elyse Swallow, Jie Zhang, (unknown), (unknown), Andrew Kageleiry, James Signorovitch	55
20	Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe 2014 ·Journal of Medical Economics ·Mario Campone, Hongbo Yang, Elizabeth Faust, Andrew Kageleiry, James Signorovitch, Jie Zhang, Haitao Gao	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact